Science Explorer Back to mapMap

Most cited papers from Paracelsus Elena Klinik Kassel

What are the most cited papers from Paracelsus Elena Klinik Kassel?

The most cited paper from Paracelsus Elena Klinik Kassel is "Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines" (Irene Litvan, Jennifer G. Goldman, Alexander I. Tröster et al., 2012), with 2,583 citations. Next come "Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria" (2,430) and "Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity" (2,038).

Showing 50 of 60 papers. Every paper with more than 187 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines Irene Litvan, Jennifer G. Goldman, Alexander I. Tröster et al. · Movement Disorders Open access 24 Jan 2012 2,583
2 Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria Günter U. Höglinger et al. · Movement Disorders Open access 3 May 2017 2,430
3 Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity Ludovico Cantuti‐Castelvetri et al. · Science Open access 20 Oct 2020 2,038
4 Restless legs syndrome/Willis–Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria – history, rationale, description, and significance Richard P. Allen, Daniel L. Picchietti, Diego Garcı́a-Borreguero et al. · Sleep Medicine Open access 17 May 2014 1,617
5 The ubiquitin pathway in Parkinson's disease Elisabeth Leroy, Rebecca L. Boyer, Georg W. J. Auburger et al. · Nature Oct 1998 1,582
6 Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study Ronald B. Postuma et al. · Brain Open access 26 Jan 2019 1,142
7 A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease Alexander A. Zimprich et al. · The American Journal of Human Genetics Open access Jul 2011 915
8 MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI Irene Litvan, Dag Aarsland, Charles H. Adler et al. · Movement Disorders Open access 9 Jun 2011 810
9 Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study Andrew D. Siderowf et al. · The Lancet Neurology Open access 13 Apr 2023 744
10 The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort KENNETH L. MAREK et al. · Annals of Clinical and Translational Neurology Open access 31 Oct 2018 717
11 Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions Juliane Winkelmann et al. · Nature Genetics 18 Jul 2007 708
12 CSF and blood biomarkers for Parkinson's disease Lucilla Parnetti, Lorenzo Gaetani, Paolo Eusebi et al. · The Lancet Neurology Open access 11 Apr 2019 692
13 α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study Brit Mollenhauer, Joseph J. Locascio, Walter Schulz‐Schaeffer et al. · The Lancet Neurology 12 Feb 2011 634
14 A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research Tanya Simuni et al. · The Lancet Neurology Open access 22 Jan 2024 626
15 The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder Anna Heintz‐Buschart, Urvashi Pandey, Tamara Wicke et al. · Movement Disorders Open access 26 Aug 2017 575
16 A Practical Guide to Immunoassay Method Validation Ulf Andréasson et al. · Frontiers in Neurology Open access 19 Aug 2015 559
17 Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal Fluid Mohammad Shahnawaz, Takahiko Tokuda, Masaaki Waragai et al. · JAMA Neurology Open access 5 Dec 2016 521
18 Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER) Claudia Trenkwalder, Bryan Kies, Monika Rudzińska et al. · Movement Disorders Open access 18 Nov 2010 443
19 Parkinson's disease sleep scale—validation of the revised version PDSS‐2 Claudia Trenkwalder, Ralf Kohnen, Birgit Högl et al. · Movement Disorders 10 Feb 2011 437
20 Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies Anne Stuendl, Marcel Kunadt, Niels Kruse et al. · Brain Open access 8 Dec 2015 436
21 Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals Stefanie Theresa Jost et al. · Movement Disorders ReviewOpen access 5 May 2023 390
22 Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration Brit Mollenhauer, Valerie Cullen, Ilana L. Kahn et al. · Experimental Neurology 15 Jun 2008 388
23 Restless legs syndrome associated with major diseases Claudia Trenkwalder, Richard P. Allen, Birgit Högl et al. · Neurology Open access 4 Mar 2016 374
24 Recommendations to Standardize Preanalytical Confounding Factors in Alzheimer’s and Parkinson’s Disease Cerebrospinal Fluid Biomarkers: An Update Marta del Campo, Brit Mollenhauer, Antonio Bertolotto et al. · Biomarkers in Medicine Aug 2012 361
25 Trial of Cinpanemab in Early Parkinson’s Disease Anthony E. Lang et al. · New England Journal of Medicine Open access 3 Aug 2022 360
26 The restless legs syndrome Claudia Trenkwalder, Walter Paulus, Arthur Scott Walters · The Lancet Neurology 19 Jul 2005 353
27 Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide Sebastian Schade, Brit Mollenhauer, Claudia Trenkwalder · Movement Disorders Clinical Practice Open access 26 Feb 2020 349
28 Summary of the recommendations of the EFNS / MDS ‐ ES review on therapeutic management of P arkinson's disease Joaquim José Ferreira et al. · European Journal of Neurology 22 Dec 2012 345
29 Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial Regina Katzenschlager, Werner H Poewe, Olivier Rascol et al. · The Lancet Neurology Open access 25 Jul 2018 334
30 Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry Piotr Lewczuk et al. · The World Journal of Biological Psychiatry Open access 27 Oct 2017 321
31 Restless legs syndrome: pathophysiology, clinical presentation and management Claudia Trenkwalder, Walter Paulus · Nature Reviews Neurology Review Jun 2010 308
32 MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity Nadiya M. Teplyuk, Brit Mollenhauer, G. Gabriely et al. · Neuro-Oncology Open access 4 Apr 2012 304
33 Gender-related differences in the burden of non-motor symptoms in Parkinson’s disease Pablo Martínez‐Martín, Cristian Falup Pecurariu, Per Odin et al. · Journal of Neurology 11 Jan 2012 292
34 Diagnostic Standards for Dopaminergic Augmentation of Restless Legs Syndrome: Report from a World Association of Sleep Medicine – International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute Diego Garcı́a-Borreguero, Richard P. Allen, Ralf Kohnen et al. · Sleep Medicine 4 Jun 2007 286
35 PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome Barbara Schormair et al. · Nature Genetics Open access 20 Jul 2008 286
36 Comorbidities, treatment, and pathophysiology in restless legs syndrome Claudia Trenkwalder, Richard P. Allen, Birgit Högl et al. · The Lancet Neurology Open access 20 Sep 2018 276
37 Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype Georgia Minakaki et al. · Autophagy Open access 4 Dec 2017 275
38 Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations Birgit Högl, Isabelle Arnulf, Cynthia L. Comella et al. · Movement Disorders 7 Oct 2010 270
39 Absence of an Orphan Mitochondrial Protein, C19orf12, Causes a Distinct Clinical Subtype of Neurodegeneration with Brain Iron Accumulation Monika Hartig et al. · The American Journal of Human Genetics Open access Oct 2011 270
40 King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation К. Ray Chaudhuri, Alexandra Rizos, Claudia Trenkwalder et al. · Movement Disorders Open access 11 Jun 2015 267
41 Treatment of restless legs syndrome: An evidence‐based review and implications for clinical practice Claudia Trenkwalder, Wayne A. Hening, Pasquale Montagna et al. · Movement Disorders Open access 16 Oct 2008 263
42 Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson’s disease Oliver Riedel, Jens Klotsche, Annika E. Spottke et al. · Journal of Neurology 5 Feb 2010 261
43 Systematic Comparison of the Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation Diana F. Lázaro, Eva Ferreira Rodrigues, Ramona Langohr et al. · PLoS Genetics Open access 13 Nov 2014 259
44 Cognitive impairment in 873 patients with idiopathic Parkinson's disease Oliver Riedel, Jens Klotsche, Annika E. Spottke et al. · Journal of Neurology Open access 18 Jan 2008 255
45 Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis Barbara Schormair et al. · The Lancet Neurology ReviewOpen access 13 Oct 2017 247
46 Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group Carlos Hugh Schenck et al. · Sleep Medicine Open access 22 Jul 2013 240
47 Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology Kathrin Doppler, Sönke Ebert, Nurcan Üçeyler et al. · Acta Neuropathologica Open access 30 Apr 2014 237
48 CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study The Parkinson’s Progression Marker Initiative et al. · Acta Neuropathologica Open access 28 Mar 2016 229
49 Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension Claudia Trenkwalder, Heike Beneš, Ludger Grote et al. · The Lancet Neurology 17 Oct 2013 229
50 Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3‐year European multicenter study with repeat [ 123 I]FP‐CIT SPECT Vicky L. Marshall et al. · Movement Disorders 2 Jan 2009 212

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.